Karen M Gallegos1, George L Drusano1, David Z D Argenio2, Ashley N Brown1. 1. Institute for Therapeutic Innovation, Department of Medicine, University of Florida, Orlando. 2. Department of Biomedical Engineering, University of Southern California, Los Angeles.
Abstract
INTRODUCTION: We evaluated the antiviral activities of ribavirin (RBV) and interferon (IFN) alfa as monotherapy and combination therapy against chikungunya virus (CHIKV). METHODS: Vero cells were infected with CHIKV in the presence of RBV and/or IFN alfa, and viral production was quantified by plaque assay. A mathematical model was fit to the data to identify drug interactions for effect. We ran simulations using the best-fit model parameters to predict the antiviral activity associated with clinically relevant regimens of RBV and IFN alfa as combination therapy. The model predictions were validated using the hollow fiber infection model (HFIM) system. RESULTS: RBV and IFN alfa were effective against CHIKV as monotherapy at supraphysiological concentrations. However, RBV and IFN alfa were highly synergistic for antiviral effect when administered as combination therapy. Simulations with our mathematical model predicted that a standard clinical regimen of RBV plus IFN alfa would inhibit CHIKV burden by 2.5 log10 following 24 hours of treatment. In the HFIM system, RBV plus IFN alfa at clinical exposures resulted in a 2.1-log10 decrease in the CHIKV burden following 24 hours of therapy. These findings validate the prediction made by the mathematical model. CONCLUSIONS: These studies illustrate the promise of RBV plus IFN alfa as a potential therapeutic strategy for the treatment of CHIKV infections.
INTRODUCTION: We evaluated the antiviral activities of ribavirin (RBV) and interferon (IFN) alfa as monotherapy and combination therapy against chikungunya virus (CHIKV). METHODS: Vero cells were infected with CHIKV in the presence of RBV and/or IFN alfa, and viral production was quantified by plaque assay. A mathematical model was fit to the data to identify drug interactions for effect. We ran simulations using the best-fit model parameters to predict the antiviral activity associated with clinically relevant regimens of RBV and IFN alfa as combination therapy. The model predictions were validated using the hollow fiber infection model (HFIM) system. RESULTS:RBV and IFN alfa were effective against CHIKV as monotherapy at supraphysiological concentrations. However, RBV and IFN alfa were highly synergistic for antiviral effect when administered as combination therapy. Simulations with our mathematical model predicted that a standard clinical regimen of RBV plus IFN alfa would inhibit CHIKV burden by 2.5 log10 following 24 hours of treatment. In the HFIM system, RBV plus IFN alfa at clinical exposures resulted in a 2.1-log10 decrease in the CHIKV burden following 24 hours of therapy. These findings validate the prediction made by the mathematical model. CONCLUSIONS: These studies illustrate the promise of RBV plus IFN alfa as a potential therapeutic strategy for the treatment of CHIKV infections.
Authors: Liviawati S Wu; Joseph E Rower; James R Burton; Peter L Anderson; Kyle P Hammond; Fafa Baouchi-Mokrane; Gregory T Everson; Thomas J Urban; David Z D'Argenio; Jennifer J Kiser Journal: Antimicrob Agents Chemother Date: 2015-02-02 Impact factor: 5.191
Authors: F Staikowsky; K Le Roux; I Schuffenecker; P Laurent; P Grivard; A Develay; A Michault Journal: Epidemiol Infect Date: 2007-04-16 Impact factor: 2.451
Authors: Xavier De Lamballerie; Véronique Boisson; Jean-Charles Reynier; Sébastien Enault; Rémi N Charrel; Antoine Flahault; Pierre Roques; Roger Le Grand Journal: Vector Borne Zoonotic Dis Date: 2008-12 Impact factor: 2.133
Authors: Angelica Cifuentes Kottkamp; Elfie De Jesus; Rebecca Grande; Julia A Brown; Adam R Jacobs; Jean K Lim; Kenneth A Stapleford Journal: J Virol Date: 2019-05-15 Impact factor: 5.103
Authors: André C Ferreira; Patrícia A Reis; Caroline S de Freitas; Carolina Q Sacramento; Lucas Villas Bôas Hoelz; Mônica M Bastos; Mayara Mattos; Natasha Rocha; Isaclaudia Gomes de Azevedo Quintanilha; Carolina da Silva Gouveia Pedrosa; Leticia Rocha Quintino Souza; Erick Correia Loiola; Pablo Trindade; Yasmine Rangel Vieira; Giselle Barbosa-Lima; Hugo C de Castro Faria Neto; Nubia Boechat; Stevens K Rehen; Karin Brüning; Fernando A Bozza; Patrícia T Bozza; Thiago Moreno L Souza Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191
Authors: Camilly P Pires de Mello; Xun Tao; Tae Hwan Kim; Jürgen B Bulitta; Jaime L Rodriquez; Justin J Pomeroy; Ashley N Brown Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Camilly P Pires de Mello; George L Drusano; Jaime L Rodriquez; Ajeet Kaushik; Ashley N Brown Journal: Viruses Date: 2018-06-09 Impact factor: 5.048